These studies are of direct clinical interest, since preclinical data indicates that TGF-β trap and IL-8 inhibitors rescue the myelofibrosis phenotype in animal models [11,25], and clinical trials with these drugs are currently under investigation [26]. Here, CXCL8 is linked to myelofibrosis.